Show simple item record

dc.contributor.advisorMorón Duarte, Lina Sofía 
dc.contributor.advisorAlvarez Larrañaga, Martha Isabel 
dc.creatorNiño Ruiz, Carmen Judith 
dc.date.accessioned2014-07-08T18:13:05Z
dc.date.available2014-07-08T18:13:05Z
dc.date.created2014-06-13
dc.date.issued2014 
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/6363
dc.descriptionLa incidencia de la tosferina ha mostrado un incremento en los últimos años; afectando predominantemente a los niños menores de 1 año, adolescentes y adultos. En el 2005 el Comité Asesor de Prácticas en Inmunización (ACIP) recomendó administrar una dosis de refuerzo de la vacuna acelular antipertussis a los adolescentes. Esta estrategia ha sido adoptada por distintos países. Sin embargo hasta el momento no existe una revisión sistemática que evalúe la efectividad de esta medida de prevención primaria. Métodos: Revisión sistemática de la literatura de artículos acerca de la efectividad de la vacuna acelular antipertussis como dosis de refuerzo en adolescentes. Resultados: La búsqueda inicial arrojó un total de 121 resultados, de los cuales solo 4 cumplieron los criterios de selección. Se evaluó en éstos, la inmunogenicidad generada contra tétanos y difteria por la vacuna Tdap vs Td con resultados significativos y similares. Además se documentó la respuesta inmunológica protectora generada por la Tdap contra tosferina. En cuanto a la reactogenicidad, en general fue baja. Discusión: La vacuna Tdap genera inmunogenicidad similar a la Td contra tétanos y difteria. Además proporciona adecuada protección contra la tosferina como dosis de refuerzo en los adolescentes. Conclusión: La evidencia disponible sugiere que se puede recomendar la vacuna Tdap como dosis de refuerzo en adolescentes entre los 10 y los 18 años de edad por su baja reactogenicidad y adecuada inmunogenicidad contra tétanos, difteria y B. Pertussis.
dc.description.abstractIntroduction: Pertussis has been considered as one of the major pathologies before the start of vaccination. It was the main cause of pathologies responsible for infantile morbidity and mortality. In recent years, there has been an increment in the number of cases of pertussis, with displacement of the disease to infants under 1 year, teenagers and adults. Thus, in 2005, the Advisory Committee on Immunization Practices (ACIP) recommended administering a booster shot of acellular pertussis vaccine for teenagers. This strategy has been adopted by different countries. Methods: Papers from the specialized literature have been queried in order to obtain information regarding the effectiveness of acellular pertussis vaccine as a booster shot in teenagers. Results: An initial exploration revealed a total of 121 results, 26 papers were pre-selected and 4 were included in the review. They were classified as level of evidence Ib. The immunogenicity of the vaccine Tdap has been tested and compared with the Td. We note that, the responses of the booster shot by the Tdap for the difteria and tetanus are not inferior to those obtained via the Td vaccine. Moreover, the responses by the Tdap shot generate a significative response against specific antigens of the Bordetella Pertussis. The most common local adverse event was the pain, predominantly, in the group that received Tdap. Discussion: The immunogenicity of the Tdap is similar to that obtained by the Td against tetanus and diphtheria. In addition, the Tdap vaccine provides adequate protection against pertussis as a booster in adolescents. Conclusions: Available evidence supports the idea of Tdap vaccine as a booster shot in teenagers in the range of 10 and 18 years old. This obeys to the low reactogenicity and adequate immunogenicity against tetanus, diphtheria and B. pertussis.
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectEfectividad, Resultado del Tratamiento, Vacunas contra Difteria, Tétanos y Tos Ferina Acelular, Adolescente.
dc.subject.ddcEnfermedades 
dc.subject.lembDifteria::Vacunación
dc.subject.lembTos ferina::Vacunación
dc.subject.lembTétanos::Vacunación
dc.titleEfectividad de la vacuna acelular antipertussis en adolescentes: una revisión sistemática
dc.typebachelorThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Pediatría
dc.publisher.programEspecialización en Pediatría
dc.publisher.departmentFacultad de medicina
dc.subject.keywordtreatment outcome, pertussis vaccine, adolescent, teenagers, teens, boostrix, adacel.
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.subject.decsVacuna contra Difteria, Tétanos y Tos Ferina
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto completo)
dc.type.hasVersioninfo:eu-repo/semantics/submittedVersion
dc.source.bibliographicCitation1. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85(40):385-400.
dc.source.bibliographicCitation2. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969-87.
dc.source.bibliographicCitation3. Tozzi AE, Celentano LP, Ciofi degli Atti ML, Salmaso S. Diagnosis and management of pertussis. Cmaj. 2005;172(4):509-15.
dc.source.bibliographicCitation4. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(1):13-5.
dc.source.bibliographicCitation5. Wheeler JG, Simmons AL. Pertussis update. Pediatr Infect Dis J. 2005;24(9):829-30.
dc.source.bibliographicCitation6. Tan T. Summary: epidemiology of pertussis. Pediatr Infect Dis J. 2005;24(5 Suppl):S35-8.
dc.source.bibliographicCitation7. Bamberger ES, Srugo I. What is new in pertussis? Eur J Pediatr. 2008;167(2):133-9.
dc.source.bibliographicCitation8. Greenberg DP. Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. Pediatr Infect Dis J. 2005;24(8):721-8.
dc.source.bibliographicCitation9. Edwards K, Freeman DM. Adolescent and adult pertussis: disease burden and prevention. Curr Opin Pediatr. 2006;18(1):77-80.
dc.source.bibliographicCitation10. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine. 2007;25(14):2634-42.
dc.source.bibliographicCitation11. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis. 2004;190(3):535-44.
dc.source.bibliographicCitation12. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555-63.
dc.source.bibliographicCitation13. Galanis E, King AS, Varughese P, Halperin SA. Changing epidemiology and emerging risk groups for pertussis. Cmaj. 2006;174(4):451-2.
dc.source.bibliographicCitation14. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J. 2005;24(5 Suppl):S25-34.
dc.source.bibliographicCitation15. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet. 2006;367(9526):1926-36.
dc.source.bibliographicCitation16. Warfel JM, Beren J, Merkel TJ. Airborne transmission of Bordetella pertussis. J Infect Dis 2012; 206:902.
dc.source.bibliographicCitation17. Bergquist SO, Bernander S, Dahnsjö H, Sundelöf B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J 1987; 6:458.
dc.source.bibliographicCitation18. Bass JW, Klenk EL, Kotheimer JB, et al. Antimicrobial treatment of pertussis. J Pediatr 1969; 75:768.
dc.source.bibliographicCitation19. Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.
dc.source.bibliographicCitation20. Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis. 2001;32(12):1691-7.
dc.source.bibliographicCitation21. Skowronski DM, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis. 2002;185(10):1448-53.
dc.source.bibliographicCitation22. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J. 2003;22(1):22-7.
dc.source.bibliographicCitation23. Guiso N, Wirsing von Konig CH, Forsyth K, Tan T, Plotkin SA. The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010. Vaccine. 29. Netherlands: Copyright A© 2010. Published by Elsevier Ltd.. All rights reserved.; 2011. p. 1115-21.
dc.source.bibliographicCitation24. Nelson JD. The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. Am J Dis Child 1978; 132:371.
dc.source.bibliographicCitation25. Centers for Disease Control and Prevention. Pertussis (Whooping Cough). Pertussis in Other Countries. http://www.cdc.gov/pertussis/countries.html.
dc.source.bibliographicCitation26. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58-61.
dc.source.bibliographicCitation27. Dworkin MS. Adults are whooping, but are internists listening? Ann Intern Med 2005; 142:832.
dc.source.bibliographicCitation28. Hewlett EL, Edwards KM. Clinical practice. Pertussis--not just for kids. N Engl J Med 2005; 352:1215.
dc.source.bibliographicCitation29. Wendelboe AM, Hudgens MG, Poole C, Van Rie A. Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants. Emerg Themes Epidemiol. 2007;4:15.
dc.source.bibliographicCitation30. Cherry JD, Heininger U. Pertussis. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia, PA: W. B. Saunders; 2003.
dc.source.bibliographicCitation31. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004; 23:985.
dc.source.bibliographicCitation32. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293.
dc.source.bibliographicCitation33. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007; 26:238.
dc.source.bibliographicCitation34. Tablas_2013_A_SEM 52. Extraido el 6 de Junio de 2014 desde http://www.ins.gov.co /lineas-de-accion/Subdireccion - Vigilancia /sivigila /Paginas /vigilancia-rutinaria.aspx
dc.source.bibliographicCitation35. Informe del evento de la vigilancia de tosferina, hasta periodo epidemiologico cuatro (IV) del año 2014. Version: 01. Extraido el 6 de junio de 2014 desde http://www.ins.gov.co:81/lineas-de-accion/Subdireccion-Vigilancia/Informe %20de%20Evento%20Epidemiolgico/TOSFERINA%20Periodo%20IV%202014. pdf
dc.source.bibliographicCitation36. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics. 1997;100(6):E10.
dc.source.bibliographicCitation37. Nieves DJ, Singh J, Ashouri N, et al. Clinical and laboratory features of pertussis in infants at the onset of a California epidemic. J Pediatr 2011; 159:1044.
dc.source.bibliographicCitation38. Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870.
dc.source.bibliographicCitation39. Tozzi AE, Ravà L, Ciofi degli Atti ML, et al. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics 2003; 112:1069.
dc.source.bibliographicCitation40. Couzigou C, Flahault A. Is pertussis being considered as a cause of persistent cough among adults? Eur J Epidemiol 2003; 18:1013.
dc.source.bibliographicCitation41. Harnden A, Grant C, Harrison T, et al. Whooping cough in school age children with persistent cough: prospective cohort study in primary care. BMJ 2006; 333:174.
dc.source.bibliographicCitation42. Laboratory manual for the diagnosis of whooping cough caused by Bordetella pertussis/ Bordetella parapertussis. Geneva, World Health Organization, 2007 (WHO/ IPV/04.14). Also available from http://www.who.int/immunization/documents/ WHO_IVB_04.14/en/index.html.)
dc.source.bibliographicCitation43. Riffelmann M, Wirsing von Konig CH, Caro V, Guiso N. Nucleic Acid amplification tests for diagnosis of Bordetella infections. J Clin Microbiol. 2005;43(10):4925-9.
dc.source.bibliographicCitation44. Njamkepo E et al. Thirty-five years’ experience with the whole-cell pertussis vaccine in France:vaccine strains analysis and immunogenicity. Vaccine, 2002, 20:1290–1294.
dc.source.bibliographicCitation45. Lai FY, Thoon KC, Ang LW, Tey SH, Heng D, Cutter JL, et al. Comparative seroepidemiology of pertussis, diphtheria and poliovirus antibodies in Singapore: waning pertussis immunity in a highly immunized population and the need for adolescent booster doses. Vaccine. 2012;30(24):3566-71.
dc.source.bibliographicCitation46. Okada K, Komiya T, Yamamoto A, Takahashi M, Kamachi K, Nakano T, et al. Safe and effective booster immunization using DtaP in teenagers. Vaccine. 2010;28(48):7626-33.
dc.source.bibliographicCitation47. Camenga DR, Kyanko K, Stepczynski J, Flaherty-Hewitt M, Curry L, Sewell D, et al. Increasing adult Tdap vaccination rates by vaccinating infant caregivers in the pediatric office. Acad Pediatr. 2012;12(1):20-5.
dc.source.bibliographicCitation48. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005;24(6 Suppl):S104-8.
dc.source.bibliographicCitation49. de Carvalho AP, Pereira EM. Acellular pertussis vaccine for adolescents. J Pediatr (Rio J). 2006;82(3 Suppl):S15-24.
dc.source.bibliographicCitation50. Singh M, Lingappan K. Whooping cough: the current scene. Chest. 2006;130(5):1547-53.
dc.source.bibliographicCitation51. Griffiths AH. Permanenent brain damage and pertussis vaccination: is the end of the saga in sight? Vaccine 1989;7:199–210.
dc.source.bibliographicCitation52. Protocolo de vigilancia en salud publica Tosferina, Version 03. Extraido el 6 de Junio de 2014 desde http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia /sivigila / Protocolos%20SIVIGILA/PRO%20Tos%20ferina.pdf
dc.source.bibliographicCitation53. Cohen S, Black A, Ross A, Mandel ED. Updated treatment and prevention guidelines for pertussis. Jaapa. 2014;27(1):19-25, quiz 6.
dc.source.bibliographicCitation54. Pickering LK, Baker CJ, Freed GL, Gall SA, Grogg SE, Poland GA, et al. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(6):817-40.
dc.source.bibliographicCitation55. Cherry JD. Pertussis vaccines for adolescents and adults. Pediatrics. 2005;116(3):755-6.
dc.source.bibliographicCitation56. Halperin SA. Pertussis–a disease and vaccine for all ages. N Engl J Med. 353. United States2005. P. 1615-7.
dc.source.bibliographicCitation57. Akinsanya-Beysolow I, Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group, Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years - United States, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:108.
dc.source.bibliographicCitation58. de Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010; 50:1339.
dc.source.bibliographicCitation59. Bechini A, Tiscione E, Boccalini S, Levi M, Bonanni P. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations. Vaccine. 2012;30(35):5179-90.
dc.source.bibliographicCitation60. Food and Drug Administration. Product approval information-licensing action, package insert: BOOSTRIX®. Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed. GlaxoSmithKline Biologicals. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005.
dc.source.bibliographicCitation61. Food and Drug Administration. Product approval information-licensing action, package insert: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed ADACELTM. Sanofi celula. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2006.
dc.source.bibliographicCitation62. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics. 2006;117(3):965-78.
dc.source.bibliographicCitation63. Wilson TR. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis. J Pediatr Health Care. 2006;20(4):229-37.
dc.source.bibliographicCitation64. Lineamiento Estratégico para la Introducción de la Vacuna TdaP (Tétanos - Difteria - Tos ferina acelular) en el Esquema del Programa Ampliado de Inmunizaciones –PAI Para Mujeres Gestantes de las cohortes 2013 y 2014. Extraido el 6 de Junio de 2014 desde http://www.minsalud.gov.co /Documentos %20y%20Publicaciones/Lineamiento%20Estrat%C3%A9gico%20para%20la%20Introducci%C3%B3n%20de%20la%20Vacuna%20TdaP.pdf
dc.source.bibliographicCitation65. Protocolo Tos Ferina 2013. Extraido el 6 de Junio de 2014 desde http://www.ins.gov.co/Noticias/Memorias%20Reunin%20Nacional%20de%20Vigilancia%20y%20Control%20e/2-8-tosferina.pdf
dc.source.bibliographicCitation66. Pichichero ME, Casey JR, Francis AB, Marsocci SM, Murphy M, Hoeger W, et al. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. Clin Pediatr (Phila). 2006;45(7):613-20.
dc.source.bibliographicCitation67. Tran Minh NN, He Q, Ramalho A, Kaufhold A, Viljanen MK, Arvilommi H, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics. 1999;104(6):e70.
dc.source.bibliographicCitation68. Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. Jama. 2005;293(24):3003-11.
dc.source.bibliographicCitation69. Southern J, Andrews N, Burrage M, Miller E. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine. 2005;23(29):3829-35.
dc.format.tipoDocumento
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARÁGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/2.5/co/

 

Reconocimientos: